Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Researchers Plan To Continue To Study COX-2 Inhibitors in Cancer Treatment and Prevention

Researchers Plan To Continue To Study COX-2 Inhibitors in Cancer Treatment and Prevention Several cyclooxygenase 2 (COX-2) inhibitors have taken a beating from recent evidence that they can cause deaths from heart attack and stroke, but some cancer researchers say that the drugs are too promising as possible chemoprevention agents to abandon them completely. Rofecoxib (Vioxx) was withdrawn from the market in September when a colon cancer chemoprevention trial revealed an increased risk of heart attacks and strokes among long-term users (see , Vol. 96, No. 23, p. 1734, "Vioxx Withdrawal Alarms Cancer Prevention Researchers"). Soon after, valdecoxib (Bextra) was shown to increase heart attacks in people who recently had coronary artery bypass surgery. Bad for celecoxib (Celebrex), the COX-2 inhibitor used most frequently in prevention trials, came in December: It also increased the risk of heart attacks in a cancer prevention trial. Drug administration was stopped on dozens of cancer prevention trials, other studies were halted, and a U.S. Food and Drug Administration hearing was planned. Two FDA panels--the Arthritis Drug Advisory Committee and the Drug Safety and Risk Management Advisory Committee--met jointly in midFebruary. Overall, they viewed the cardiovascular risk as a class effect among the group of COX-2 inhibitors. But they voted to keep on the market the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the National Cancer Institute Oxford University Press

Researchers Plan To Continue To Study COX-2 Inhibitors in Cancer Treatment and Prevention

Researchers Plan To Continue To Study COX-2 Inhibitors in Cancer Treatment and Prevention

Journal of the National Cancer Institute , Volume 97 (8) – Apr 20, 2005

Abstract

Several cyclooxygenase 2 (COX-2) inhibitors have taken a beating from recent evidence that they can cause deaths from heart attack and stroke, but some cancer researchers say that the drugs are too promising as possible chemoprevention agents to abandon them completely. Rofecoxib (Vioxx) was withdrawn from the market in September when a colon cancer chemoprevention trial revealed an increased risk of heart attacks and strokes among long-term users (see , Vol. 96, No. 23, p. 1734, "Vioxx Withdrawal Alarms Cancer Prevention Researchers"). Soon after, valdecoxib (Bextra) was shown to increase heart attacks in people who recently had coronary artery bypass surgery. Bad for celecoxib (Celebrex), the COX-2 inhibitor used most frequently in prevention trials, came in December: It also increased the risk of heart attacks in a cancer prevention trial. Drug administration was stopped on dozens of cancer prevention trials, other studies were halted, and a U.S. Food and Drug Administration hearing was planned. Two FDA panels--the Arthritis Drug Advisory Committee and the Drug Safety and Risk Management Advisory Committee--met jointly in midFebruary. Overall, they viewed the cardiovascular risk as a class effect among the group of COX-2 inhibitors. But they voted to keep on the market the

Loading next page...
 
/lp/oxford-university-press/researchers-plan-to-continue-to-study-cox-2-inhibitors-in-cancer-iYixMpQI6b

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Oxford University Press
Copyright
Journal of the National Cancer Institute, Vol. 97, No. 8, © Oxford University Press 2005, all rights reserved.
ISSN
0027-8874
eISSN
1460-2105
DOI
10.1093/jnci/97.8.552
pmid
15840872
Publisher site
See Article on Publisher Site

Abstract

Several cyclooxygenase 2 (COX-2) inhibitors have taken a beating from recent evidence that they can cause deaths from heart attack and stroke, but some cancer researchers say that the drugs are too promising as possible chemoprevention agents to abandon them completely. Rofecoxib (Vioxx) was withdrawn from the market in September when a colon cancer chemoprevention trial revealed an increased risk of heart attacks and strokes among long-term users (see , Vol. 96, No. 23, p. 1734, "Vioxx Withdrawal Alarms Cancer Prevention Researchers"). Soon after, valdecoxib (Bextra) was shown to increase heart attacks in people who recently had coronary artery bypass surgery. Bad for celecoxib (Celebrex), the COX-2 inhibitor used most frequently in prevention trials, came in December: It also increased the risk of heart attacks in a cancer prevention trial. Drug administration was stopped on dozens of cancer prevention trials, other studies were halted, and a U.S. Food and Drug Administration hearing was planned. Two FDA panels--the Arthritis Drug Advisory Committee and the Drug Safety and Risk Management Advisory Committee--met jointly in midFebruary. Overall, they viewed the cardiovascular risk as a class effect among the group of COX-2 inhibitors. But they voted to keep on the market the

Journal

Journal of the National Cancer InstituteOxford University Press

Published: Apr 20, 2005

There are no references for this article.